VYNE Therapeutics Inc.
VYNE
$1.85
$0.0452.49%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 501.00K | 493.00K | 486.00K | 423.00K | 424.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 501.00K | 493.00K | 486.00K | 423.00K | 424.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 501.00K | 493.00K | 486.00K | 423.00K | 424.00K |
| SG&A Expenses | 13.19M | 13.91M | 13.97M | 13.91M | 13.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.14M | 38.19M | 31.33M | 31.19M | 29.68M |
| Operating Income | -43.64M | -37.70M | -30.84M | -30.76M | -29.26M |
| Income Before Tax | -39.80M | -33.95M | -27.86M | -28.50M | -27.87M |
| Income Tax Expenses | 4.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.81 | -33.95 | -27.86 | -28.50 | -27.87 |
| Earnings from Discontinued Operations | -27.00K | -55.00K | -568.00K | -577.00K | -579.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.83M | -34.00M | -28.43M | -29.08M | -28.45M |
| EBIT | -43.64M | -37.70M | -30.84M | -30.76M | -29.26M |
| EBITDA | -12.77M | -6.81M | -13.03M | -23.33M | -29.19M |
| EPS Basic | -0.94 | -0.86 | -2.58 | -5.43 | -7.01 |
| Normalized Basic EPS | -0.58 | -0.53 | -1.51 | -3.29 | -4.27 |
| EPS Diluted | -0.94 | -0.86 | -2.58 | -5.43 | -7.02 |
| Normalized Diluted EPS | -0.58 | -0.53 | -1.51 | -3.29 | -4.27 |
| Average Basic Shares Outstanding | 170.35M | 159.03M | 119.73M | 80.42M | 41.09M |
| Average Diluted Shares Outstanding | 170.35M | 159.03M | 119.73M | 80.42M | 41.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |